Shareholders of Cipla Medpro South Africa have finally given nod to Mumbai-based Cipla’s offer to acquire 100% stake in the foreign company. Earlier this year, Cipla offered close to $500 million to buy out South African affiliate Cipla Medpro by sweetening its bid by 17% after earlier talks stalled over price. In November Cipla offered $215 million for 51% of the company. So, the company would offer 10 South African rand per share, up from its initial bid of 8.55 rand and valuing the company at around 4.5 billion rand ($508 million).
Cipla supplies the bulk of the South African company's drugs through a long-standing agreement; however it has never owned a stake in the Cape Town-based company. This development will give Cipla a direct connect to consumers in South Africa. It also helps the company to integrate its marketing or front-end arm in South Africa with its manufacturing, regulatory and research units.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: